Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Clinical PET system for early stage breast cancer diagnosis

European researchers have developed a clinical PET system with the highest resolution and sensitivity in the market, specifically dedicated to breast cancer detection in early stages.

18 May 2011

Nano Bridging Molecules SA receives CE marking certification for SurfLink dental product

Nano Bridging Molecules SA, A Swiss med-tech company announced that it has received CE Mark (Conformité Européenne) approval to begin marketing its SurfLink® Dental product. With its bio mimicking properties, SurfLink® Dental has been shown to allow for natural and permanent integration of dental implants for the first time. Bone seems to perceive the SurfLink® Dental product as ‘body-like’ and integrates the implant with a natural healing process, resulting in a quicker healing and a more stable integration, than without this product.

18 May 2011

Nordic Naturals' dietary supplements earn NSF certification

Nordic Naturals has earned certification from NSF International, verifying that its new LEED-designed corporate headquarters complies with Good Manufacturing Practices as set forth in NSF/ANSI Standard 173-2008, Dietary Supplements, Section 8.

17 May 2011

Epichem signs exclusive distributor agreement with AR Brown

Australian supplier of API analytical standards Epichem, announced today it has signed an exclusive distributor agreement with a leading Japanese Life Sciences supplier company, AR Brown, for sales to Japan, Taiwan, China and South Korea.

17 May 2011

Teva signs definitive agreement to acquire Taiyo

Teva Pharmaceutical Industries Ltd. announced today that it has signed a definitive agreement to acquire 57% of the shares in privately-held Taiyo Pharmaceutical Industry Co. Ltd. for $460 million in cash paid to private shareholders.

16 May 2011

pSivida resubmits ILUVIEN NDA to FDA for diabetic macular edema treatment

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its licensee, Alimera Sciences, Inc., resubmitted a New Drug Application for the investigational drug ILUVIEN for the treatment of diabetic macular edema (DME) to the U.S. Food and Drug Administration (FDA) on May 12, 2011 to address questions raised in the Complete Response Letter (CRL) Alimera received in December 2010.

16 May 2011

Scientists 'tinker' with HIV drug chemistry hoping to reduce costs

The Clinton Health Access Initiative, founded by former President Bill Clinton, with funding from the Bill & Melinda Gates Foundation and the U.K. government, has hired former pharmaceutical company scientists "to tinker with the chemistry used to synthesize a key [HIV] drug, tenofovir" in an effort to reduce "the cost of manufacturing," the Wall Street Journal reports.

13 May 2011

Cipher first quarter net revenue decreases to $0.7 million

Cipher Pharmaceuticals Inc. today announced its financial and operational results for the three months ended March 31, 2011.

12 May 2011

Winner Medical second quarter net sales increase 27% to $33.2 million

Winner Medical Group Inc., a leading manufacturer of medical dressings, medical disposables and non-woven fabric made from 100% natural PurCotton products in China, today reported consolidated financial results for the second quarter ended March 31, 2011.

11 May 2011

China Pharma first quarter revenue increases 20% to $18.1 million

China Pharma Holdings, Inc., a fully-integrated specialty pharmaceuticals company in China, today announced financial results for the quarter ended March 31, 2011.

11 May 2011

SAFC, Oncolytics Biotech sign commercial supply agreement for REOLYSIN

Oncolytics Biotech Inc. today announced that it has entered into a commercial supply agreement with SAFC, a Division of Sigma-Aldrich Corporation, for the commercial manufacture of REOLYSIN, Oncolytics proprietary reovirus.

11 May 2011

Symphogen to present second-generation Sympress platform at ESACT conference

Symphogen, a private biopharmaceutical company developing superior antibody therapeutics to treat cancer, infectious and autoimmune diseases, announced today that second-generation enhancements to the company's SYMPRESS manufacturing and quality control platform will be presented in an oral presentation entitled "Recombinant antibody mixtures; optimization of cell line generation and single-batch manufacturing processes" by Dr. Søren K. Rasmussen, Principal Scientist, Symphogen at the upcoming European Society for Animal Cell Technology conference in Vienna on May 17, 2011.

11 May 2011

Pacira Pharmaceuticals reports net loss of $9.8 million for first quarter 2011

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced financial results for the first quarter ended March 31, 2011, provided an update on the execution of its pre-commercial and launch strategies for EXPAREL, and reiterated 2011 financial guidance.

11 May 2011

EMD Millipore inaugurates new Shanghai Biopharmaceutical Technical Center

EMD Millipore, the Life Science division of Merck KGaA of Germany, today opened its state-of-the-art Biopharmaceutical Technical and Training Center in Shanghai, China. The 28,000 square foot facility will provide support, training and validation services to EMD Millipore's biopharmaceutical customers with operations in China.

11 May 2011

Insmed first quarter revenues decrease to $1.6 million

Insmed Incorporated, a biopharmaceutical company, today reported results for the first quarter ended March 31, 2011.

10 May 2011

Simcere first quarter total revenue increases 5.1% to RMB482.2 million

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today reported unaudited financial results for the first quarter ended March 31, 2011.

10 May 2011

CorMedix first quarter net loss decreases to $1.9 million

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced its financial results for the quarter ended March 31, 2011.

10 May 2011

Mathematical approach can make combination vaccines more affordable for developing countries

Combination vaccines for young children are commonly used in industrialized nations because they provide protection for multiple diseases in one single injection. However, combination vaccines are prohibitively expensive for developing countries and may not available until several years later, or when market prices are more affordable.

10 May 2011

OncoGenex first quarter revenue decreases to $1.2 million

OncoGenex Pharmaceuticals, Inc. today announced its first quarter financial results and provided an update on current events and activities.

10 May 2011

Unigene first quarter net loss decreases 58% to $6.6 million

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced first quarter financial results for the period ended March 31, 2011. The Company highlighted significant progress achieved in the first quarter with the execution of its turnaround strategy.

9 May 2011